Literature DB >> 16804707

Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.

Timothy Y Y Lai1, Jasmine W S Ngai, Wai-Man Chan, Dennis S C Lam.   

Abstract

PURPOSE: To evaluate the effects of hydroxychloroquine on visual field and multifocal electroretinography (mfERG) and their correlations in patients taking hydroxychloroquine.
METHODS: This was a cross-sectional study in which patients on hydroxychloroquine therapy underwent automated 10-2 threshold static visual field examination and mfERG recordings. Non-parametric unadjusted and age-adjusted Spearman correlation coefficients rho were calculated between the cumulative dose of hydroxychloroquine and the visual field mean deviation (MD) and pattern standard deviation (PSD) values; and the mfERG response amplitudes and peak latencies. Correlation analysis was also performed between the visual field MD and PSD values and the mfERG response amplitudes and peak latencies.
RESULTS: A total of 26 eyes in 13 patients were analyzed. The mean duration of hydroxychloroquine therapy was 4.9 years and the mean cumulative dose was 574 g. No significant correlation was found between the cumulative dose of hydroxychloroquine and the visual field MD and PSD values. There were significant correlations between the cumulative dose of hydroxychloroquine and mfERG N1 and P1 response amplitudes for the central rings (ring 1-3). The correlations between the dose of hydroxychloroquine and mfERG N1 and P1 response amplitudes were strongest for the paracentral ring 2 (rho =-0.63 and rho =-0.62, respectively, P = 0.001). Significant correlations were also found between the visual field MD values and mfERG response amplitudes of various ring eccentricities.
CONCLUSIONS: In patients on hydroxychloroquine, mfERG response amplitude correlated with both the 10-2 visual field MD values and with the cumulative dose of hydroxychloroquine used. The use of mfERG can provide objective measurement of retinal function in patients on hydroxychloroquine and may provide supplementary quantitative information to visual field findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804707     DOI: 10.1007/s10633-006-9006-0

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  27 in total

1.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.

Authors:  Michael F Marmor; Ronald E Carr; Michael Easterbrook; Ayad A Farjo; William F Mieler
Journal:  Ophthalmology       Date:  2002-07       Impact factor: 12.079

2.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.

Authors:  G D Levy; S J Munz; J Paschal; H B Cohen; K J Pince; T Peterson
Journal:  Arthritis Rheum       Date:  1997-08

3.  The dilemma of hydroxychloroquine screening: new information from the multifocal ERG.

Authors:  Michael F Marmor
Journal:  Am J Ophthalmol       Date:  2005-11       Impact factor: 5.258

Review 4.  Ocular safety of hydroxychloroquine.

Authors:  H N Bernstein
Journal:  Ann Ophthalmol       Date:  1991-08

Review 5.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

6.  Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.

Authors:  Raj K Maturi; Minzhong Yu; Richard G Weleber
Journal:  Arch Ophthalmol       Date:  2004-07

7.  Ocular effects and safety of antimalarial agents.

Authors:  M Easterbrook
Journal:  Am J Med       Date:  1988-10-14       Impact factor: 4.965

8.  Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography.

Authors:  Scott C So; Thomas R Hedges; Joel S Schuman; Maria Luz Amaro Quireza
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2003 May-Jun

9.  Detecting chloroquine retinopathy: electro-oculogram versus colour vision.

Authors:  A S Neubauer; K Samari-Kermani; U Schaller; U Welge-Lübetaen; G Rudolph; T Berninger
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

10.  The use of Amsler grids in early chloroquine retinopathy.

Authors:  M Easterbrook
Journal:  Ophthalmology       Date:  1984-11       Impact factor: 12.079

View more
  19 in total

1.  The mfERG response topography with scaled stimuli: effect of the stretch factor.

Authors:  Charlotte M Poloschek; Michael Bach
Journal:  Doc Ophthalmol       Date:  2009-02-20       Impact factor: 2.379

Review 2.  Testing retinal toxicity of drugs in animal models using electrophysiological and morphological techniques.

Authors:  Ido Perlman
Journal:  Doc Ophthalmol       Date:  2008-11-09       Impact factor: 2.379

3.  MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study.

Authors:  Mustafa Iftikhar; Ramandeep Kaur; April Nefalar; Bushra Usmani; Saleema Kherani; Isra Rashid; Etienne Schönbach; Michelle Petri; Hendrik P N Scholl; Syed M Shah
Journal:  Retina       Date:  2019-03       Impact factor: 4.256

4.  Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.

Authors:  Susann Missner; Ulrich Kellner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-04       Impact factor: 3.117

5.  Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.

Authors:  Paul Salu; André Uvijls; Pierre van den Brande; Bart P Leroy
Journal:  Doc Ophthalmol       Date:  2010-04-16       Impact factor: 2.379

6.  [Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy].

Authors:  R Bergholz; K Rüther; H Tillack; A M Joussen; J Schroeter
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

7.  Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.

Authors:  Kimberly E Stepien; Dennis P Han; Jonathan Schell; Pooja Godara; Jungtae Rha; Joseph Carroll
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

8.  Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Hande Husniye Telek; Nilufer Yesilirmak; Gulten Sungur; Yaprak Ozdemir; Nesibe Karahan Yesil; Firdevs Ornek
Journal:  Doc Ophthalmol       Date:  2017-08-29       Impact factor: 2.379

Review 9.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

10.  Evaluation of optical coherence tomography angiography parameters in patients treated with Hydroxychloroquine.

Authors:  Mohammadreza Akhlaghi; Farzan Kianersi; Hamed Radmehr; Alireza Dehghani; Afsaneh Naderi Beni; Pegah Noorshargh
Journal:  BMC Ophthalmol       Date:  2021-05-11       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.